Related Experiment Video

Updated: Aug 19, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Mechanism of CDK5/p25 binding by CDK inhibitors

Marina Mapelli1, Lucia Massimiliano, Claudia Crovace

  • 1Structural Biology Unit, Department of Experimental Oncology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy.

Journal of Medicinal Chemistry
|February 4, 2005
PubMed

Insights

Researchers crystallized cyclin-dependent kinase 5 (CDK5) with its activator p25, revealing its structure with inhibitors. This provides a foundation for developing new drugs targeting neurodegenerative diseases like Alzheimer's and Parkinson's.

Area of Science:

  • Structural biology
  • Neuroscience
  • Pharmacology

Background:

  • Cyclin-dependent kinases (CDKs) regulate cell cycle progression and are cancer targets.
  • CDK5 is crucial for neuronal development and implicated in neurodegenerative diseases.
  • Developing selective CDK5 inhibitors is a key therapeutic goal.

Purpose of the Study:

  • To determine the high-resolution crystal structure of CDK5/p25 complexed with inhibitors.
  • To understand the structural basis for inhibitor binding and selectivity.
  • To investigate the role of the glycine-rich loop in CDK5 regulation and inhibitor interaction.

Main Methods:

  • Generation of improved CDK5/p25 crystals.
  • X-ray crystallography to solve structures at 2.2-2.3 Å resolution.
  • Biochemical assays to study inhibitor binding and effects of phosphorylation.

Main Results:

  • The structure of CDK5/p25 with (R)-roscovitine was solved, explaining stereoisomer preference.
  • Roscovitine induced an unusual collapsed conformation of the glycine-rich loop.
  • Phosphorylation effects on roscovitine binding to the glycine-rich loop were investigated.

Conclusions:

  • The CDK5/p25 crystal structure provides a detailed molecular understanding of inhibitor binding.
  • This structural information is valuable for designing selective CDK5 inhibitors.
  • The findings facilitate the development of novel therapeutics for neurodegenerative diseases.

More Related Videos

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay12:26

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay

Published on: May 3, 2018

Experimental Approaches to Study Mitochondrial Localization and Function of a Nuclear Cell Cycle Kinase, Cdk113:15

Experimental Approaches to Study Mitochondrial Localization and Function of a Nuclear Cell Cycle Kinase, Cdk1

Published on: February 25, 2016

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
Positive Regulator Molecules01:45

Positive Regulator Molecules

To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.